Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance

Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; however, therapies targeting EGFR have demonstrated limited effectiveness and led to drug resistance. miR-203 levels are down-regulated in clinical samples of primary prostate cancer and further reduced in metastatic prostate cancer. Here we show that ectopic miR-203 expression displayed reduced bone metastasis and induced sensitivity to tyrosine kinase inhibitors (TKIs) treatment in a xenograft model. Our results demonstrate that the induction of bone metastasis and TKI resistance require miR-203 down-regulation, activation of the EGFR pathway via altered expression of EGFR ligands (EREG and TGFA) and anti-apoptotic proteins (API5, BIRC2, and TRIAP1). Importantly, a sufficient reconstitution of invasiveness and resistance to TKIs treatment was observed in cells transfected with anti-miR-203. In prostate cancer patients, our data showed that miR-203 levels were inversely correlated with the expression of two EGFR ligands, EREG and TGFA, and an EGFR dependent gene signature. Our results support the existence of a miR-203, EGFR, TKIs resistance regulatory network in prostate cancer progression. We propose that the loss of miR-203 is a molecular link in the progression of prostate cancer metastasis and TKIs resistance characterized by high EGFR ligands output and anti-apoptotic proteins activation.

[1]  Julia Schüler,et al.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs , 2009, Nature Cell Biology.

[2]  Zhaohui S. Qin,et al.  Coordinated regulation of polycomb group complexes through microRNAs in cancer. , 2011, Cancer cell.

[3]  D. Berney,et al.  Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancer , 2012, Genes, chromosomes & cancer.

[4]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[5]  Hyun-soo Cho,et al.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.

[6]  Stefania Staibano,et al.  Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[8]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[9]  Rameen Beroukhim,et al.  An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.

[10]  G. Miller,et al.  Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines , 1992, Molecular carcinogenesis.

[11]  W. Isaacs,et al.  ras gene mutations in human prostate cancer. , 1990, Cancer research.

[12]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[13]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[14]  D. Forrest,et al.  E2f2 induces cone photoreceptor apoptosis independent of E2f1 and E2f3 , 2013, Cell Death and Differentiation.

[15]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[16]  K. Helin,et al.  Polycomb Complex 2 Is Required for E-cadherin Repression by the Snail1 Transcription Factor , 2008, Molecular and Cellular Biology.

[17]  S. Nelson,et al.  Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA , 2014, Science.

[18]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[19]  G. Miller,et al.  Comparison of ras activation in prostate carcinoma in Japanese and American men , 1997, The Prostate.

[20]  R. Knight,et al.  miR-203 represses ‘stemness’ by repressing ΔNp63 , 2008, Cell Death and Differentiation.

[21]  L. Tran,et al.  Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. , 2012, Cancer research.

[22]  D. Troyer,et al.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  D. Esposito,et al.  Lentivirus‐mediated bifunctional cell labeling for in vivo melanoma study , 2009, Pigment cell & melanoma research.

[24]  W Abou-Kheir,et al.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms , 2013, Oncogene.

[25]  Kyung Chul Moon,et al.  BRAF and KRAS mutations in prostatic adenocarcinoma , 2006, International journal of cancer.

[26]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[27]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[28]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[29]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[30]  S. Srivastava,et al.  The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence , 2013, International journal of cancer.

[31]  B. Nicke,et al.  The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component. , 2004, Molecular biology of the cell.

[32]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[33]  S. Korsmeyer,et al.  bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes , 1991, Cell.

[34]  M. Becich,et al.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process , 2007, BMC Cancer.

[35]  Yuri B Schwartz,et al.  Polycomb complexes and epigenetic states. , 2008, Current opinion in cell biology.

[36]  K. Kelly,et al.  Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. , 2010, Cancer research.

[37]  Yihong Ma,et al.  Identification of novel E2F1-regulated genes by microarray. , 2002, Archives of biochemistry and biophysics.

[38]  A. Traish,et al.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth , 2009, British Journal of Cancer.

[39]  J. Sun,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[40]  F. Siannis,et al.  Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. , 2008, The Lancet. Oncology.

[41]  A. Bozec,et al.  EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment , 2010, Pharmaceuticals.

[42]  A. Haese*,et al.  Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.

[43]  R. Ray,et al.  Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. , 2011, Genes & cancer.

[44]  George A. Calin,et al.  MicroRNAs — the micro steering wheel of tumour metastases , 2009, Nature Reviews Cancer.

[45]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[46]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[47]  M. Niger,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Isaac Crespo,et al.  A Novel Network Integrating a miRNA-203/SNAI1 Feedback Loop which Regulates Epithelial to Mesenchymal Transition , 2012, PloS one.

[49]  M. Susin,et al.  Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. , 1993, Cancer investigation.

[50]  T. Shiraishi,et al.  Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations. , 1998, Anticancer research.

[51]  J. Baselga,et al.  Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.

[52]  L. Chin,et al.  BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma , 2008, PloS one.

[53]  Jun-Yuan Ji,et al.  Functional Identification of Api5 as a Suppressor of E2F-Dependent Apoptosis In Vivo , 2006, PLoS genetics.

[54]  C. Croce,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature medicine.

[55]  John Calvin Reed,et al.  bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. , 1992, Cancer research.

[56]  M. Kasper,et al.  MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma , 2012, Oncogenesis.

[57]  Rajvir Dahiya,et al.  Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis , 2010, Clinical Cancer Research.

[58]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[59]  J. Abraham,et al.  Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. , 1995, Genes & development.

[60]  Dong Hu,et al.  Critical and Reciprocal Regulation of KLF4 and SLUG in Transforming Growth Factor β-Initiated Prostate Cancer Epithelial-Mesenchymal Transition , 2011, Molecular and Cellular Biology.

[61]  K. Kelly,et al.  Activation of the RalGEF/Ral Pathway Promotes Prostate Cancer Metastasis to Bone , 2007, Molecular and Cellular Biology.

[62]  Y. Huang,et al.  Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells , 2010, Oncogene.